Societal CDMO, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. David Enloe Jr.
- Full Time Employees
- 258
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1 E. Uwchlan Ave Exton PA United States of America 19341
- IPO Date
- Mar 7, 2014
- CIK
- 0001588972
- Website
- societalcdmo.com
- Similar Companies
- Business
- Societal CDMO, Inc. (SCTL) operates as a contract development and manufacturing organization (CDMO) focused on solving complex formulation and manufacturing challenges primarily for small molecule therapeutics; it provides therapeutic development, end-to-end regulatory support, pre-Investigational New Drug (IND) capabilities, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services. The company specializes in handling DEA-controlled substances and modified-release dosage forms including tablets and capsules, with expertise in analytical development, formulation development, clinical supply, and commercialization across early-phase to late-phase projects. Founded in 1982 and headquartered in Gainesville, Georgia, Societal CDMO maintains bi-coastal facilities totaling 145,000 square feet in Gainesville, Georgia, and San Diego, California, serving the global pharmaceutical market. In April 2024, CoreRx, Inc. completed its acquisition of Societal CDMO for $1.10 per share in cash through a tender offer and subsequent merger, making Societal CDMO a wholly owned subsidiary of CoreRx and resulting in the delisting of its common stock from the Nasdaq Capital Market. This transaction, valued at approximately $130 million, enhances the combined entity's capabilities in small molecule formulation development, manufacturing, and packaging. Prior to the acquisition, Societal CDMO signed multiple new CDMO service agreements and project expansions involving analytical methods, technical transfers, GMP batch manufacturing, and packaging for novel therapeutic candidates.
CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.
CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.
SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL
SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL
Why Is Societal CDMO (SCTL) Stock Up 133% Today?
SCTL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Societal CDMO, Inc. Is Fair to Shareholders
Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
Societal CDMO Reports Inducement Grants for New Staff
Societal CDMO, Inc. (SCTL) Q3 2023 Earnings Call Transcript
Societal CDMO Reports Third Quarter 2023 Financial Results
Societal CDMO to Report Financial Results for Third Quarter 2023 on November 8, 2023
Societal CDMO Reports Inducement Grants for New Staff
Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference
Societal CDMO Announces Corporate Restructuring
Societal CDMO Secures Project Expansion Agreements With Several Existing Customers
Societal CDMO Announces Closing of $8.3 Million Public Offering of Common Stock
Societal CDMO stock drops on discounted offering
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock
Societal CDMO Announces Appointment of Matt Arens to Board of Directors